Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from AbbVie Inc, Constellation Pharmaceuticals, Inc., and Incyte Corporation.
Advances in™: What Does the Future Hold for Treatment and Management of MPNs?
Release Date: April 30, 2021
Expiration Date: April 30, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by educational grants from AbbVie Inc, Constellation Pharmaceuticals, Inc., and Incyte Corporation.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is directed toward hematologists and medical oncologists interested in the treatment of hematologic malignancies. Other allied health care professionals, including nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with hematologic malignancies will also be invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the role of clinical and cytogenic characteristics in risk stratification and treatment planning for the management of myeloproliferative neoplasms (MPNs)
- Assess the rationale for, as well as efficacy and safety data from, ongoing clinical trials evaluating emerging therapies for the treatment of myelofibrosis (MF) and polycythemia vera (PV)
- Determine eligible patients with MF or PV based on disease characteristics who may benefit from participation in a clinical trial
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
Faculty
Executive Director
Mays Cancer Center
University of Texas Health San Antonio MD Anderson Cancer Center
San Antonio, TX
Disclosures: Grant Research Support: Bristol Myers Squibb, CTI BioPharma, Incyte Corporation, Sierra Oncology; Consultant: AbbVie, Blueprint, Bristol Myers Squibb, Incyte Corporation, Novartis, Protagonist Therapeutics, Telios pharma.
Associate Professor
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm Program
Hematology Consultant, Cancer Network
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas
Disclosures: Grant/Research Support: Affymetrix, SagerStrong Foundation. Consultant: AbbVie, Blueprint Medicines, Bristol Myers Squibb, Celgene, DAVA Oncology, ImmunoGen, Incyte, LFB Biotechnologies, MustangBio, Novartis, Pacylex Pharmaceuticals, Roche Diagnostics, Sprinter Science + Business Media, Stemline Therapeutics.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.